{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:35:21Z","timestamp":1792794921732,"version":"4.5.0"},"reference-count":74,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health, Rome, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Bacteriophage (phage) therapy, including monophage preparations, phage cocktails, engineered phages, and phage-derived enzymes, has re-emerged as a potential option for difficult-to-treat and biofilm-associated infections in the context of rising antimicrobial resistance. Recent scientific and regulatory developments, such as the 2024 World Health Organization Bacterial Priority Pathogens List and the introduction of the European Pharmacopoeia general chapter 5.31 on phage therapy medicinal products, highlight the growing interest in establishing quality, safety, and governance standards for clinical implementation. This narrative review provides an overview of current clinical applications of phage therapy, drawing on published case reports, case series, early-phase clinical studies, and regulatory experiences across different healthcare settings. Clinical use has been reported in respiratory, urinary tract, musculoskeletal, cardiovascular, and device-associated infections, particularly in cases involving multidrug-resistant pathogens, often in combination with antibiotics. At the same time, the biological characteristics of phages, such as strain specificity, adaptive composition of phage cocktails, and the need for individualized formulations, pose significant regulatory and translational challenges. Access to phage therapy currently relies on heterogeneous regulatory mechanisms, including compassionate use programmes, magistral preparations, named-patient pathways, and other national frameworks. Overall, phage therapy represents a promising strategy for selected infections, but its broader clinical adoption will depend on harmonized regulatory approaches, robust quality standards, and the generation of stronger clinical evidence to support safe and scalable use.<\/jats:p>","DOI":"10.3390\/ph19010162","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:28:12Z","timestamp":1768555692000},"page":"162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge"],"prefix":"10.3390","volume":"19","author":[{"given":"Anna","family":"Gallina","sequence":"first","affiliation":[{"name":"IRCCS ISMETT, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7695-3769","authenticated-orcid":false,"given":"Matteo","family":"Gallina","sequence":"additional","affiliation":[{"name":"Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), School of Specialization in Hospital Pharmacy, University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-6535","authenticated-orcid":false,"given":"Andrea","family":"Cona","sequence":"additional","affiliation":[{"name":"IRCCS ISMETT, 90127 Palermo, Italy"},{"name":"UPMC Italy, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Vitulo","sequence":"additional","affiliation":[{"name":"IRCCS ISMETT, 90127 Palermo, Italy"},{"name":"UPMC Italy, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mularoni","sequence":"additional","affiliation":[{"name":"IRCCS ISMETT, 90127 Palermo, Italy"},{"name":"UPMC Italy, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-000X","authenticated-orcid":false,"given":"Alessio","family":"Provenzani","sequence":"additional","affiliation":[{"name":"IRCCS ISMETT, 90127 Palermo, Italy"},{"name":"UPMC Italy, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators (2024). Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050. Lancet, 404, 1199\u20131226."},{"key":"ref_2","unstructured":"World Health Organization (2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, World Health Organization."},{"key":"ref_3","unstructured":"World Health Organization (2022, March 31). New Report Calls for Urgent Action to Avert Antimicrobial Resistance Crisis. Available online: https:\/\/www.who.int\/news\/item\/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.addr.2018.08.001","article-title":"Phage therapy for respiratory infections","volume":"133","author":"Chang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zalewska-Pi\u0105tek, B., and Pi\u0105tek, R. (2020). Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. coli. Antibiotics, 9.","DOI":"10.3390\/antibiotics9060304"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Markiewicz-Gospodarek, A., Kozio\u0142, M., Tobiasz, M., Baj, J., Radzikowska-B\u00fcchner, E., and Przekora, A. (2022). Burn wound healing: Clinical complications, medical care, treatment, and dressing types. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19031338"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ferry, T., Kolenda, C., Batailler, C., Gustave, C.-A., Lustig, S., Malatray, M., Fevre, C., Josse, J., Petitjean, C., and Chidiac, C. (2020). Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection. Front. Med., 7.","DOI":"10.3389\/fmed.2020.570572"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-394438-2.00001-3","article-title":"Phage therapy\u2014History from Twort and d\u2019Herelle through Soviet experience to current approaches","volume":"83","author":"Chanishvili","year":"2012","journal-title":"Adv. Virus Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/viru.25991","article-title":"A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens","volume":"5","author":"Wittebole","year":"2014","journal-title":"Virulence"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01462-20","DOI":"10.1128\/mBio.01462-20","article-title":"Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry","volume":"11","author":"Liu","year":"2020","journal-title":"mBio"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s13205-024-04101-8","article-title":"Phage therapy: A novel approach against multidrug-resistant pathogens","volume":"14","author":"Kapoor","year":"2024","journal-title":"3 Biotech"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2273567","DOI":"10.1080\/21505594.2023.2273567","article-title":"Potential of phage depolymerase for the treatment of bacterial biofilms","volume":"14","author":"Guo","year":"2023","journal-title":"Virulence"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.06330-11","article-title":"Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15","volume":"56","author":"Pouillot","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hitchcock, N.M., Nunes, D.D.G., Shiach, J., Hodel, K.V.S., Barbosa, J.D.V., Rodrigues, L.A.P., Coler, B.S., Soares, M.B.P., and Badar\u00f3, R. (2023). Current clinical landscape and global potential of bacteriophage therapy. Viruses, 15.","DOI":"10.3390\/v15041020"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","article-title":"Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): The randomised, open-label, first part of a two-part phase 2 trial","volume":"24","author":"Kim","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","unstructured":"Locus Biosciences (2025, October 21). A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. coli (ELIMINATE Trial). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05488340."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Aranaga, C., Pantoja, L.D., Mart\u00ednez, E.A., and Falco, A. (2022). Phage therapy in the era of multidrug resistance in bacteria: A systematic review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094577"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1128\/CMR.15.2.167-193.2002","article-title":"Biofilms: Survival mechanisms of clinically relevant microorganisms","volume":"15","author":"Donlan","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/1040841X.2012.723675","article-title":"Bacteriophage virion-associated peptidoglycan hydrolases: Potential new enzybiotics","volume":"39","author":"Donovan","year":"2013","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e02071-21","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","article-title":"Distinguishing between resistance, tolerance and persistence to antibiotic treatment","volume":"14","author":"Brauner","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00924-19","DOI":"10.1128\/AAC.00924-19","article-title":"Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa","volume":"64","author":"Tkhilaishvili","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2021.05.027","article-title":"Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection","volume":"83","author":"Tkhilaishvili","year":"2021","journal-title":"J. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00044-24","DOI":"10.1128\/cmr.00044-24","article-title":"Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A review with a focus on multidrug-resistant Gram-negative bacterial infections","volume":"37","author":"Siopi","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mestrovic, T., Matijasic, M., Peric, M., Cipcic Paljetak, H., Baresic, A., and Verbanac, D. (2020). The role of gut, vaginal, and urinary microbiome in urinary tract infections: From bench to bedside. Diagnostics, 11.","DOI":"10.3390\/diagnostics11010007"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1365-2672.2012.05432.x","article-title":"Bacteriophages are synergistic with bacterial interference for the prevention of Pseudomonas aeruginosa biofilm formation on urinary catheters","volume":"113","author":"Liao","year":"2012","journal-title":"J. Appl. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e01281-19","DOI":"10.1128\/AAC.01281-19","article-title":"A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient","volume":"64","author":"Kuipers","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/22221751.2020.1747950","article-title":"Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae","volume":"9","author":"Bao","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1099\/jmm.0.029744-0","article-title":"Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection","volume":"60","author":"Khawaldeh","year":"2011","journal-title":"J. Med. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: A systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: A case report","volume":"169","author":"Hoyle","year":"2018","journal-title":"Res. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamaoto.2019.1191","article-title":"Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus","volume":"145","author":"Ooi","year":"2019","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/23744235.2024.2379492","article-title":"Phage therapy: An alternative treatment modality for MDR bacterial infections","volume":"56","author":"Pal","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful treatment of antibiotic-resistant, polymicrobial bone infection with bacteriophages and antibiotics combination","volume":"69","author":"Gelman","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Onsea, J., Soentjens, P., Djebara, S., Merabishvili, M., Depypere, M., Spriet, I., De Munter, P., Debaveye, Y., Nijs, S., and Vanderschot, P. (2019). Bacteriophage application for difficult-to-treat musculoskeletal infections: Development of a standardized multidisciplinary treatment protocol. Viruses, 11.","DOI":"10.3390\/v11100891"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dky263","article-title":"Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages","volume":"73","author":"Ferry","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.healun.2019.01.001","article-title":"Novel bacteriophage therapy for treatment of left ventricular assist device infection","volume":"38","author":"Aslam","year":"2019","journal-title":"J. Heart Lung Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E.C., Warnecke, G., Tudorache, I., Shrestha, M., Schmitto, J.D., Martens, A., and Rojas, S.V. (2020). Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050232"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol. Med. Public Health"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5694\/mja2.50274","article-title":"Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus","volume":"211","author":"Gilbey","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.healun.2022.01.018","article-title":"Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German Heart Center Berlin experience","volume":"41","author":"Tkhilaishvili","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0041-1345(03)00525-6","article-title":"Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man","volume":"35","author":"Mulczyk","year":"2003","journal-title":"Transplant. Proc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MOT.0000000000001029","article-title":"Role of bacteriophage therapy for resistant infections in transplant recipients","volume":"27","author":"Nicholls","year":"2022","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.healun.2019.01.1306","article-title":"Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: An ISHLT Registry\u2013based analysis","volume":"38","author":"Lay","year":"2019","journal-title":"J. Heart Lung Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.2147\/IDR.S301153","article-title":"Management of multidrug resistant infections in lung transplant recipients with cystic fibrosis","volume":"14","author":"Vazirani","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.healun.2021.04.011","article-title":"Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients","volume":"40","author":"Shah","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1513\/AnnalsATS.201606-431OC","article-title":"Reemergence of lower-airway microbiota in lung transplant patients with cystic fibrosis","volume":"13","author":"Syed","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/cid\/ciad072","article-title":"1-year outcomes of lung transplantation for coronavirus disease 2019-associated end-stage lung disease in the United States","volume":"76","author":"Okumura","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/s41598-018-38318-4","article-title":"Fibrin glue as a local drug-delivery system for bacteriophage PA5","volume":"9","author":"Rubalskii","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Paul, K., Merabishvili, M., Hazan, R., Christner, M., Herden, U., Gelman, D., Khalifa, L., Yerushalmy, O., Coppenhagen-Glazer, S., and Harbauer, T. (2021). Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses, 13.","DOI":"10.3390\/v13091785"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Terwilliger, A., Clark, J., Karris, M., Hernandez-Santos, H., Green, S., Aslam, S., and Maresso, A. (2021). Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infection. Viruses, 13.","DOI":"10.3390\/v13102049"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S416","DOI":"10.1093\/cid\/ciad528","article-title":"Phage therapy in lung transplantation: Current status and future possibilities","volume":"77","author":"Aslam","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.healun.2021.04.014","article-title":"The lung microbiome in lung transplantation","volume":"40","author":"McGinniss","year":"2021","journal-title":"J. Heart Lung Transplant."},{"key":"ref_59","unstructured":"World Health Organization (2025). Bacteriophages and Their Use in Combating Antimicrobial Resistance, World Health Organization."},{"key":"ref_60","unstructured":"European Medicines Agency (2022). Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections, European Medicines Agency. CPMP\/EWP\/558\/95 Rev 3."},{"key":"ref_61","unstructured":"European Medicines Agency (2024, February 19). Workshop on the Therapeutic Use of Bacteriophages. Available online: https:\/\/www.ema.europa.eu\/en\/events\/workshop-therapeutic-use-bacteriophages."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yang, Q., Le, S., Zhu, T., and Wu, N. (2023). Regulations of phage therapy across the world. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1250848"},{"key":"ref_63","unstructured":"European Medicines Agency, and Committee for Medicinal Products for Human Use (CHMP) (2023). Concept Paper on the Establishment of a Guideline on the Development and Manufacture of Human Medicinal Products Specifically Designed for Phage Therapy, EMA. EMA\/CHMP\/BWP\/486838\/2023."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Faltus, T. (2024). The medicinal phage\u2014Regulatory roadmap for phage therapy under EU pharmaceutical legislation. Viruses, 16.","DOI":"10.3390\/v16030443"},{"key":"ref_65","unstructured":"European Directorate for the Quality of Medicines & HealthCare (EDQM) (2024). New General Chapter on Phage Therapy Medicinal Products (5.31) Adopted and Pre-Published on the EDQM Website, European Directorate for the Quality of Medicines & HealthCare (EDQM)."},{"key":"ref_66","unstructured":"(2025). Phage therapy medicinal products (5.31). European Pharmacopoeia, European Directorate for the Quality of Medicines & HealthCare (EDQM). [11th ed.]. Supplement 11.6."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Pirnay, J.P., Verbeken, G., Ceyssens, P.J., Huys, I., De Vos, D., Ameloot, C., and Fauconnier, A. (2018). The magistral phage. Viruses, 10.","DOI":"10.3390\/v10020064"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ejhpharm-2020-002242","article-title":"Role of the hospital pharmacist in an Italian antimicrobial stewardship programme","volume":"29","author":"Polidori","year":"2022","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s11096-020-01089-y","article-title":"Multidrug-resistant gram-negative organisms: A review of recently approved antibiotics and novel pipeline agents","volume":"42","author":"Provenzani","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_71","unstructured":"SUKL (2025, October 21). Contents of Supplement 11.6 of the European Pharmacopoeia. Available online: https:\/\/www.edqm.eu\/documents\/52006\/1777875\/Contents%20of%20supplement%2011.6.pdf\/d197f894-1ea4-80ca-cae7-56c2c1102c46?t=1719211202232."},{"key":"ref_72","unstructured":"Minist\u00e8re de la D\u00e9fense (2017). Final Report Summary\u2014Phagoburn: Evaluation of Phage Therapy for the Treatment of Escherichia coli and Pseudomonas aeruginosa Burn Wound Infections (Phase I\u2013II Clinical Trial), European Commission."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"001895","DOI":"10.1099\/jmm.0.001895","article-title":"Current status of clinical trials for phage therapy","volume":"73","author":"Uchechukwu","year":"2024","journal-title":"J. Med. Microbiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","article-title":"Phage therapy: From biological mechanisms to future directions","volume":"186","author":"Strathdee","year":"2023","journal-title":"Cell"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:37:39Z","timestamp":1768556259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ph19010162"],"URL":"https:\/\/doi.org\/10.3390\/ph19010162","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}